

The European [MOMENTUM](#) project, funded under Horizon Europe program with a contribution of approximately six million euros, focuses on mild cognitive impairment in patients with chronic kidney disease. This condition affects approximately 750 million people worldwide and over 80 million in Europe.

"Chronic kidney disease," explains **Norberto Perico, Medical Director of the Mario Negri Clinical Center**, "was recently recognized by the WHO as a global health priority. Nevertheless, cognitive decline related to this disease remains underdiagnosed, understudied, and inadequately managed, despite the high risk of progression to dementia."

MOMENTUM's goal is to clarify the mechanisms linking chronic kidney disease to mild cognitive decline and identify new tools for early diagnosis and potential therapeutic interventions. Led by [Biogem](#) and the [Mario Negri Institute](#) in Italy, the project involves an international network of partners from ten countries: Italy, Denmark ([Aarhus University](#)), Germany ([University of Greifswald](#)), Spain ([University of Navarra](#)), Sweden ([Karolinska Institute](#)), Austria ([European Kidney Patients' Federation](#)), the United Kingdom ([University of Nottingham](#)), Latvia ([University of Latvia](#)), Switzerland ([University of Zurich, Centre Hospitalier Universitaire Vaudois](#)), and Ireland ([Pintail Ltd](#)).

Launched on 01 June 2026, the international consortium of leading experts will carry out an innovative research program over the next four years through clinical studies, experimental models, and translational analyses. Patient benefit will remain a key focus throughout to ensure the project's research is ethically grounded and addresses patient needs.

Ortensio Zecchino, President of Biogem, emphasizes: "The collaboration represents one of MOMENTUM's strengths: a synergy that has allowed us to build a competitive scientific proposal at the European level and that will continue to guide the project's development in the coming years."

"The MOMENTUM project," concludes **Giuseppe Remuzzi, Director of the Mario Negri Institute**, "allows us to look to the future, creating new opportunities for the early diagnosis of mild cognitive impairment in patients with chronic kidney disease. Our goal is to promote targeted interventions that can bring concrete and substantial benefits to patients, their families, and the entire healthcare system."

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HaDEA). Neither the European Union nor the granting authority can be held responsible for them."



**Funded by
the European Union**